Tumor Immune Cells Hijack Metabolism to Silence NK Cell Defenses

Natural killer (NK) cells are among the immune system's most potent anti-cancer weapons. But tumors have evolved sophisticated ways to neutralize them. A new study published in Nature Cancer uncovers a previously unknown metabolic circuit that tumor-infiltrating regulatory T cells (Ti-Tregs) exploit to disable NK cells — with significant implications for cancer immunotherapy.

The researchers focused on Ti-Tregs, a subset of immune cells that normally prevent autoimmunity but in tumors become a major barrier to effective anti-cancer responses. They discovered that Ti-Tregs dramatically upregulate glutamate dehydrogenase 1 (GDH1), an enzyme that elevates levels of alpha-ketoglutarate (α-KG). In the lactate-rich environment typical of solid tumors, GDH1 itself undergoes a modification called lactylation, which further amplifies α-KG production.

This elevated α-KG then fuels the activity of ALKBH5, an RNA demethylase, which promotes Wnt2 gene expression in Ti-Tregs. The resulting WNT2 signaling drives NK cells into senescence — a dysfunctional, growth-arrested state where they can no longer effectively kill cancer cells. This lactate-to-α-KG-to-WNT2 circuit essentially converts Ti-Tregs into engines of NK cell dysfunction.

Critically, the researchers showed that disrupting this circuit reverses the damage. Inhibiting GDH1 or deleting the lactate transporter SLC16A1 specifically in Ti-Tregs reduced NK cell senescence and dramatically improved the outcomes of adoptive NK cell transfer therapy in preclinical models. These results suggest that combining metabolic inhibitors targeting this pathway with NK cell therapies could meaningfully boost anti-tumor immunity.

Limitations include that findings are from preclinical models, and the clinical translatability remains to be established. The full paper was not accessible; this summary is based on the published abstract.